Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

Paul McCroneHenry FisherClare KnightRebecca HardingAnne K SchlagDavid J NuttJoanna C Neill

Published in: Psychological medicine (2023)

Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base.

Keyphrases

sleep quality
depressive symptoms
early onset
drug induced
electronic health record
big data
decision making
human health
machine learning
physical activity
climate change
risk assessment